Georgia vs Mus: HIV-positive TB patients on ART (antiretroviral therapy)
Georgia
100.0%
in 2024
Mus
100.0%
in 2024
Georgia rank
1st
Mus rank
1st
HIV-positive TB patients on ART (antiretroviral therapy) over time
- Georgia
- Mus
How they compare
Georgia currently reports 100.0% against 100.0% in Mus, a difference of 0.0%.
The two have swapped places 10 times across 21 shared years of data; in 2004 it was Mus ahead.
Georgia ranks 1st and Mus ranks 1st of 144 countries.
Across the 3 decades both report, Georgia averaged higher in 2 and Mus in 1.
Head to head by decade
| Decade | Georgia | Mus | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 76.5% | 72.8% | 3.7% | Georgia |
| 2010s | 89.8% | 86.2% | 3.6% | Georgia |
| 2020s | 96.6% | 100.0% | 3.4% | Mus |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv-positive tb patients on art (antiretroviral therapy), Georgia or Mus?
- Georgia, at 100.0% against 100.0% in Mus as of 2024.
- What is the difference in hiv-positive tb patients on art (antiretroviral therapy) between Georgia and Mus?
- 0.0%, with Georgia ahead.
- How many years of comparable data are there for Georgia and Mus?
- 21 years are reported by both, from 2004 to 2024.
- How do Georgia and Mus rank globally for hiv-positive tb patients on art (antiretroviral therapy)?
- Georgia ranks 1st and Mus ranks 1st of 144 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as HIV-positive TB patients on ART (antiretroviral therapy) (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.